abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

This page is not available in Burmese and is being displayed in English

Company Response

9 Aug 2006

Author:
GlaxoSmithKline

Statement from GSK regarding GSK patents and patent applications directed to a specific formulation of Combivir

GSK offices in Thailand and India have recently been subject to demonstrations against GSK’s patents applications for COMBID/COMBIVIR in those countries. Prior to these demonstrations GSK decided to abandon its patents and patent applications directed to a specific formulation of Combivir wherever they exist. This includes the patent applications which were the subject of the demonstrations in Thailand and India.

Timeline